Wanxiang Healthcare Investments (WHI) is the corporate venture capital arm of Wanxiang America, the US subsidiary of Wanxiang Group Corporation. It invests in early to growth-stage healthcare technology companies, with an emphasis on digital health, medical devices, and biotechnology.
80% of their portfolio is in Healthcare. Their most common stage is series-a (40% of deals). Average disclosed round size is $19.9M (across 4 rounds with reported amounts).
Portfolio
5
Fund Size
—
Top Stage
Series A
Last 12 Mo
0
Team
AA
Amit Aysola
Managing Director
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
DealsAvg Round Size
Portfolio
5 investments
| Company | Round | Amount | Date |
|---|---|---|---|
 Carallel | Series A | $8.2M | Jan 2022 |
 Endotronix | Series D | $45M | Sep 2018 |
 Exo Imaging | Growth | — | — |
 Watershed Health | Unknown | $13.6M | — |
 QbD Vision | Series A | $13M | — |
Top Co-Investors
FCA Venture Partners2 shared
EQT Life Sciences1 shared
Illumina Ventures1 shared
SJF Ventures1 shared
Blu Ventures1 shared
Scale Venture Partners1 shared
Aperture Venture Partners1 shared
SV Health Investors1 shared
Seroba Life Sciences1 shared
Action Potential Venture Capital1 shared
AJU IB Investment1 shared
Creative Ventures1 shared
Solasta Ventures1 shared
Intel Capital1 shared
TDK Ventures1 shared
Bold Capital Partners1 shared
OSF HealthCare1 shared
Nautilus Venture Partners1 shared
MassMutual1 shared
Impact Engine1 shared
Last updated: 8 September 2026